Skip to main content
Premium Trial:

Request an Annual Quote

Cellzome Expands Proteomics Collaboration with Novartis

NEW YORK, July 25 (GenomeWeb News) - Cellzome said today that it has expanded a proteomics-based collaboration with Novartis that the companies initially entered in September 2004.

 

The expansion "is in line with the terms of the original agreement between the two companies," Cellzome said. 

 

Since September, Cellzome said it has mapped the protein networks of signaling pathways implicated in several therapeutic areas and has used this information to characterize various Novartis compounds. Under the terms of the expanded agreement, Cellzome said it will provide "more in-depth functional analyses of target candidates and signaling aspects of the disease pathways."

 

Novartis has made a "substantial equity investment" in Cellzome and will also contribute an undisclosed amount of research funding for two years with the option of extending the collaboration for a further two years, Cellzome said.

 

Terms of the agreement also include lead compound development options for both companies in exchange for licenses, milestone payments, and royalties.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.